Phase 2 Thyroid Cancer Trial, Recruiting (NCT04927416)

Phase 2 Thyroid Cancer Trial, Recruiting NCT04927416 Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Condition: Thyroid Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04927416 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Thyroid Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be male or female and 18 years of age or older.
If you have differentiated thyroid cancer (DTC) or Hürthle cell thyroid cancer (HTC): your cancer must have spread locally or to other parts of the body, AND either not respond to radioactive iodine (RAI) treatment based on imaging scans, OR your disease must have gotten worse after RAI treatment according to standard measurement guidelines.
If you have medullary thyroid cancer (MTC): you must have cancer that has spread locally or to other parts of the body, OR be suspected of having advanced or spread MTC with a calcitonin blood level above 500 pg/mL.

Who may not be able to join:

People who are pregnant or breastfeeding (based on self-report).
People with serious underlying health conditions that would make it unsafe to do diagnostic testing or treatment, such as kidney failure, serious heart failure, or another active non-thyroid cancer.
People who are unable to give their own informed consent to participate in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joanna Klubo-Gwiezdzinska, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phone: (301) 451-7710

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04927416

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase: Phase 2

Status: Recruiting

Condition: Thyroid Cancer

Trial contact: (301) 451-7710

More information: https://clinicaltrials.gov/study/NCT04927416

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be male or female and 18 years of age or older.
If you have differentiated thyroid cancer (DTC) or Hürthle cell thyroid cancer (HTC): your cancer must have spread locally or to other parts of the body, AND either not respond to radioactive iodine (RAI) treatment based on imaging scans, OR your disease must have gotten worse after RAI treatment according to standard measurement guidelines.
If you have medullary thyroid cancer (MTC): you must have cancer that has spread locally or to other parts of the body, OR be suspected of having advanced or spread MTC with a calcitonin blood level above 500 pg/mL.

Who may not be able to join:

People who are pregnant or breastfeeding (based on self-report).
People with serious underlying health conditions that would make it unsafe to do diagnostic testing or treatment, such as kidney failure, serious heart failure, or another active non-thyroid cancer.
People who are unable to give their own informed consent to participate in the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry

ClinicalTrials.gov

Start date

25 October 2021

Est. completion

30 November 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Prevalence of patients with metastatic RAI-non-avid or RAI-non-responsive thyroid cancer whose tumors are characterized by a high SSTR2 expression by imaging with 68Ga-DOTATATE PET/CT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov